Prana continues Alzheimer's drug trial in Australia

07/4/2013 | RTT News · Bloomberg Businessweek

An Australian hospital has cleared Prana Biotechnology's request to conduct a 12-month extension study of PBT2, the company's Alzheimer's disease drug candidate. PET imaging will be used to examine changes in the brains of Alzheimer's patients who have received PBT2 treatment for 12 months as part of the company's IMAGINE trial.

View Full Article in:

RTT News · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA